CEBPZ and acute myeloid leukemia: Overall, even though NGS studies in CBF-AML have revealed that the mutational profile is dominated by events in cellular proliferation pathways like RAS, KIT, or FLT3, these findings suggest that the use of anti-apoptotic agents might be of particular interest in this patient group.